Rethinking Treatment for mHSPC: Insights from Dr. Karim Fizazi
/in Expert Insights, Observational, Retrospective studies/by MaxRetrospective study: Real-World Effectiveness of Apalutamide in mHSPC
/in Observational, Retrospective studies/by MaxNew Blood Test Predicts Prognosis for Advanced Prostate Cancer Patients
/in Observational, Post-hoc/by MaxBone-Modifying Agents Linked to Improved Survival in Advanced Prostate Cancer
/in Observational, Retrospective studies/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxRethinking the “Lower is Better” Approach to LDL-C: Examining the Relationship Between Low LDL-C and Prostate Cancer Risk in Non-Hypertensive Men
/in Observational, Retrospective studies/by MaxThe Role of HSD3B1 in Prostate Cancer Progression and Treatment
/in Observational, Retrospective studies/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/in Observational, Post-hoc, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy